128 results about "Enteritis" patented technology

The invention discloses lactobacillus plantarum capable of relieving enteritis and toxicity of polystyrene nano-plastics, and the preservation number of the lactobacillus plantarum is CGMCC (China General Microbiological Culture Collection Center) NO.31420. The lactobacillus plantarum can be used for relieving enteritis and toxicity of polystyrene nano-plastics. The strain is obtained by separating and purifying baby feces, and can grow on an MRS culture medium, and the bacterial colony is round, off-white, smooth and opaque. Experiments show that the lactobacillus plantarum can effectively adsorb PS-NPs, promote the PS-NPs to be discharged along with excrement, reduce accumulation of the PS-NPs in organs, and significantly reduce toxicity and inflammatory response of organs such as liver and kidney of mice. In addition, the strain can repair the intestinal barrier function, regulate liver metabolism and relieve enteritis symptoms. The invention further provides a probiotic preparation containing the strain, and the probiotic preparation can be prepared into granules, capsules, tablets or oral liquid and the like and is used for preventing or treating intestinal injury and inflammatory diseases caused by PS-NPs. The strain is safe and efficient, and has a wide application prospect.

The invention provides a cobalt monatomic nano-enzyme system modified by phospholipid polyethylene glycol carboxyl. The cobalt monatomic nano-enzyme system comprises a cobalt monatomic nano-enzyme composite core and phospholipid polyethylene glycol carboxyl compounded on the surface of cobalt monatomic nano-enzyme, the cobalt monatomic nano-enzyme composite core comprises a cobalt monatomic nano-enzyme and ginsenoside loaded on the cobalt monatomic nano-enzyme. The invention also provides a bifidobacterium synergetic cobalt monatomic nano-enzyme system which is formed by combining cobalt monatomic nano-enzyme with ginsenoside Rb1 and further delivering the cobalt monatomic nano-enzyme and ginsenoside Rb1 through bifidobacterium bifidum for targeted therapy of enteritis. The combination of Co SA and Rb1 can enhance the anti-inflammatory efficacy by adjusting a key immune signal pathway, and bifidobacterium bifidum can ensure targeted delivery of microbiota and promote intestinal barrier repair. The synergistic three-component strategy integrating monatomic nano-enzyme antioxidation, natural drug immunoregulation and probiotic targeting is provided, and a promising treatment platform is provided for accurate intervention of IBD.

The invention belongs to the field of microorganisms, and particularly relates to lactococcus lactis Jlus 880314 and application thereof. The strain is classified and named as Lactococcus lactis, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing; the preservation number of the strain is CGMCC No. 33961. Time-of-flight mass spectrometry analysis shows that nisin exists in a metabolite of the strain, and the strain can be used for producing nisin. The compound shows an excellent and wide antibacterial function in antibacterial experiments, can be used for preparing antibacterial drugs, particularly has a remarkable inhibiting effect on growth of gram-negative bacteria and fungi, can be used for preparing drugs for relieving or treating enteritis, or preparing drugs, nourishment or health care products for regulating gastrointestinal tract micro-ecological balance of people or animals, and can be used for preparing medicines for relieving or treating enteritis. The compound can also be used for preparing antibacterial food additives and / or animal feed additives. A hemolysis experiment result shows that hemolysis is avoided, toxic and side effects are small, and wide development prospects and application values are achieved.

The invention provides a strain of high-temperature-resistant and inflammation-relieving Witzia ciliaris and an application thereof, the high-temperature-resistant and inflammation-relieving Witzia ciliaris is Witzia ciliaris CN985 and is preserved in the China Center for Type Culture Collection (CCTCC), the preservation date is April 7, 2024, and the preservation number is CCTCC NO: M 2024641. The invention further provides a preparation method of the high-temperature-resistant and inflammation-relieving Witzia ciliaris strain for preventing and treating inflammation of the high-temperature-resistant and inflammation-relieving Witzia ciliaris strain for preventing and treating inflammation of the high-temperature-resistant and inflammation-relieving Witzia ciliaris strain. The invention provides a brand new strain of Witzia ciliaris CN985, which is resistant to high temperature, has better acid resistance and bile resistance, and has no hemolysis risk when being applied to a human body. The Witzia coagulans CN985 has excellent antibacterial performance, and especially can significantly inhibit streptococcus pyogenes, salmonella enteritidis and / or group B streptococcus; besides, experimental results show that the Witzia ciliaris CN985 can relieve enteritis, improve the immunity of the organism and relieve pharyngitis, and especially when the Witzia ciliaris CN985 and the phytobacterium plantarum CE18 are combined for use, the Witzia ciliaris CN985 and the phytobacterium plantarum CE18 have a synergistic interaction effect, so that the relieving effect on enteritis can be remarkably improved.

The present invention provides a strain of the genus Alistipes as well as a pharmaceutical composition comprising the strain or an extract of the strain. The strain and the pharmaceutical composition disclosed by the invention can be used for remarkably relieving such symptoms as weight loss, shortened colon length, inflammatory factor release and the like of an enteritis object, and do not have toxic or side effects. Therefore, the another mycobacterium strain or the active extract of the another mycobacterium strain can be used for preparing pharmaceutical compositions and fermented foods for relieving enteritis, and has a very wide application prospect.

The invention provides a decapterus maruadsi deepwater net cage culture method, and belongs to the technical field of decapterus maruadsi culture. According to the method, the submersible net cage is adopted, the decapterus maruadsi is located in the optimal growth water layer at the temperature of 20-25 DEG C all the year round according to rising and falling of seasons (surface water temperature), a guide pipe is adopted for fixed-point feed feeding, and the feed coefficient is reduced to 1.25 or below. According to the method, a water temperature-feeding amount-allicin-probiotics coupling model is established, the enteritis incidence rate in the high-temperature period is controlled within 2%, and annual continuous growth of decapterus maruadsi in deep and far sea is achieved.

The invention relates to the technical field of medical image processing, and discloses a digestive enteritis pathological section image adaptive feature processing method. The method comprises the following steps: constructing a multi-scale feature analysis model based on histological features of a digestive enteritis pathological section to extract texture features and morphological features of different tissue levels in the pathological section; then constructing an adaptive feature optimization strategy, and dynamically adjusting feature selection parameters according to feature data output by the multi-scale feature analysis model; then performing joint operation on the multi-scale feature analysis model and the adaptive feature optimization strategy according to the selected pathological section sample type to obtain an optimized feature data set; and finally, according to the optimized feature data set, establishing feature representation of the digestive enteritis pathological section image. The method can comprehensively extract pathological features, dynamically optimize feature selection parameters, improve feature data set quality and feature characterization accuracy, adapt to different sample types and meet pathological analysis requirements.

The invention relates to a novel polypeptide and application thereof. The polypeptide provided by the invention is short in peptide chain and faster and better in absorption. Experimental results show that the polypeptide provided by the invention shows an obvious enteric cavity dilatation relieving effect in pharmacodynamic tests of a zebra fish inflammatory bowel disease model and a rat inflammatory bowel disease model. The polypeptide provided by the invention has a remarkable colitis relieving effect, and can be used for preparing a medicine for treating enteritis, especially a medicine for treating ulcerative colitis.

The invention relates to an enhanced adipose-derived mesenchymal stem cell and application thereof in preparation of a medicine for treating enteritis, and belongs to the technical field of cell biology. The invention provides an enhanced adipose-derived mesenchymal stem cell. The enhanced adipose-derived mesenchymal stem cell is an adipose-derived mesenchymal stem cell of an overexpressed CNDP2 gene. According to the method, only a carrier for expressing the CNDP2 gene needs to be transfected in the adipose-derived mesenchymal stem cells, a complex and difficult-to-control gene editing technology is not needed, the operation is simple and easy, and the operation can be completed in a common laboratory, so that the aging process of the adipose-derived mesenchymal stem cells can be delayed, and the in-vitro culture activity and the in-vivo enteritis resistance of the adipose-derived mesenchymal stem cells can be enhanced. The experimental period is short, the use condition is not harsh, and clinical application can be better adapted.

The invention discloses a traditional Chinese medicine navel pill for treating constipation, diarrhea and chronic enteritis and a preparation method of the traditional Chinese medicine navel pill, and belongs to the technical field of traditional Chinese medicine. The preparation method comprises the following steps: weighing the raw materials, mixing, crushing and sieving to obtain mixed medicine powder, adding honey into the mixed medicine powder, stirring and kneading until the mixture is sticky, and preparing pills. The navel pill is applied to the navel, two-way conditioning of constipation and diarrhea is achieved through the synergistic effect of traditional Chinese medicine, chronic enteritis can be treated in a targeted mode, intestinal mucosa is effectively repaired, the intestinal inflammation state is improved, the navel pill has the advantages of being safe and convenient to apply, high in bioavailability, mild and free of side effects, stimulation of oral medicine to gastrointestinal tracts is avoided, and the curative effect is good. The food is suitable for digestion function conditioning of different people.

The present application provides a kind of complex probiotic paste, which combines Enterococcus faecalis, Saccharomyces cerevisiae and vitamin B 12 Producing lactic acid bacteria of canine source, adds prebiotics, flavoring substances and auxiliary substances such as paste matrix preparation.In the paste, the viable count of Enterococcus faecalis, Saccharomyces cerevisiae and lactic acid bacteria is 1-2:1-2:1-8;Paste matrix includes fructooligosaccharide 0.5-3%, psyllium husk powder 0.1-2%, goat milk powder 2-8%, chicken liver powder 1-5%, potassium sorbate 0.5-2%, xanthan gum 1-4%, and the balance is water.The above-mentioned complex probiotic paste can be stably stored for 56 days at 4 DEG C and normal temperature dry place, has good storage stability, good safety, and can adjust intestinal flora and increase the content of intestinal lactic acid bacteria.The above-mentioned complex probiotic paste has good palatability and oral tolerance for pets such as dogs and cats, and has good therapeutic effect on DSS-induced chronic enteritis diarrhea and vitamin B 12 Deficiency.

The present invention relates to the use of an animal feed additive composition for controlling the growth of undesirable microorganisms, said composition comprising glycerides, vegetable oils, tannins and / or saponins, the glycerol ester is selected from the group consisting of glycerol monopropionate, glycerol dipropionate and glycerol tripropionate, glycerol monobutyrate, glycerol dibutyrate and glycerol tributyrate, glycerol monovalerate, glycerol divalerate and glycerol trivalerate, and mixtures thereof. The invention also relates to the use of the animal feed additive composition for promoting intestinal growth, alleviating or alleviating effects from necrotizing enteritis, modulating intestinal flora and / or as an additive to drinking water.

The present invention relates to a strain of Lactobacillus johnsonii N5 and its application in preventing and treating enteritis and diarrhea. Lactobacillus johnsonii N5), was deposited in the China Center for Type Culture Collection on February 10, 2023, with the deposit number CCTCC NO: M2023104. The Lactobacillus johnsonii N5 was isolated from the fecal microorganisms of piglets resistant to heat stress-induced diarrhea. This Lactobacillus johnsonii N5 has the effect of alleviating enteritis and diarrhea, which is specifically reflected in: significantly enhancing the expression of intestinal epithelial tight junction proteins and cytoprotective heat shock protein 70, improving the immune balance of animal intestinal T cells, enhancing immune tolerance, and reducing the degree of intestinal inflammation and the occurrence of diarrheal diseases in animals. Therefore, Lactobacillus johnsonii N5 has a significant effect in preventing and treating diarrhea and related intestinal inflammatory diseases.

The invention relates to the technical field of functional food preparation, in particular to a composition capable of improving colitis and a preparation method thereof, and the composition comprises glutamine, a composite plant extract, a zinc source and soluble dietary fibers. Wherein the compound plant extract comprises hericium erinaceus extract, ginseng extract and astragalus extract; the zinc source is zinc glycinate, zinc gluconate and the like; the soluble dietary fiber is fructo-oligosaccharide, inulin, galactomannan oligosaccharide and the like. The preparation method comprises the following steps: directly carrying out dry mixing or carrying out fluidized bed granulation on glutamine to obtain particles A, mixing the composite plant extract and the dietary fibers with ethanol, carrying out spray drying to obtain particles B, and carrying out three-dimensional mixing on the particles B and the zinc source. The composition can maintain the homeostasis of intestinal epithelial cells, reduce oxidative stress and inflammatory response, promote mucosal repair and effectively improve ulcerative colitis, Crohn's disease and chemoradiotherapy-related intestinal mucositis through multi-target action.

The invention provides an application of N4BP1 in preparation of an anti-enteritis drug, relates to the technical field of biomedicine, and particularly provides an application of N4BP1 as an inhibition target in preparation of an anti-enteritis drug. Researches show that the deletion of N4BP1 can alleviate colon pathological changes and weight loss caused by DSS, increase the survival days of mice, and reduce the generation of inflammatory factors and chemotactic factors. In addition, DSS can cause increase of N4BP1 expression in mice. Therefore, occurrence and development of enteritis can be inhibited by knocking out the N4BP1, the N4BP1 inhibitor or the N4BP1 neutralizing antibody, namely, the N4BP1 can become a new target spot for treating enteritis. Meanwhile, the expression of the N4BP1 can also be used as a new index for enteritis detection.

The invention belongs to the technical field of disease control in aquaculture, and particularly relates to a hippocampus enteritis pathogen separation and identification and medication screening method based on a high-throughput sequencing technology, which comprises the following steps: collecting intestinal tissues of a diseased hippocampus and a healthy hippocampus, respectively preparing tissue homogenate, and freezing for preservation; the method comprises the following steps: extracting DNA (Deoxyribose Nucleic Acid) of microorganisms of an intestinal tissue sample, performing 16SrDNA high-throughput sequencing, analyzing intestinal flora composition, and determining dominant bacteria; selecting and screening a culture medium according to dominant bacteria, and performing pathogenic bacterium separation and purification on intestinal tissues of the diseased hippocampus; dNA of the purified strain is extracted, 16S rDNA amplification and sequencing are carried out, and the species of pathogenic bacteria are identified through sequence comparison; according to the method, the diversity and abundance differences of microorganisms in the sick hippocampus and the healthy hippocampus are compared through a high-throughput sequencing technology, and targeted separation, identification and drug sensitivity screening are further carried out by taking statistically significant difference bacteria as the guidance of potential pathogenic bacteria.

The application discloses application of a natural oyster zinc peptide product in preparation of a medicine for preventing and treating enteritis. The application verifies the function of the natural oyster zinc peptide product in preventing and treating enteritis through animal experiments, the natural oyster zinc peptide product can improve the apparent symptoms of ulcerative colitis of mice caused by DSS by regulating the oxidation stress level, relieving the inflammatory reaction, maintaining the intestinal barrier and reducing the cell apoptosis, and the natural oyster zinc peptide product can also regulate the intestinal flora and metabolic products of the intestinal flora of the enteritis mice, so that the intestinal inflammation is relieved. The natural oyster zinc peptide product used in the application has good safety, compared with common anti-inflammatory and immunity-enhancing medicines, the natural oyster zinc peptide product has lower cost and no side effect, and the effect of relieving enteritis is remarkable. Therefore, the natural oyster zinc peptide product has a good prospect in development of medicines for preventing and treating enteritis.

The application relates to application of iron-nitrogen doped graphene in preparation of anti-radioactive enteritis drugs and belongs to the technical field of biological medicines. ZIF-8 powder, 1,10-phenanthroline powder, iron (II) acetate powder and a grinding medium are placed in a closed container to perform mechanical ball milling treatment to obtain a mixed powder; under the protection of inert gas, the mixed powder is placed in a preheated tube furnace to perform pyrolysis treatment, and is cooled to room temperature to obtain iron-nitrogen doped graphene. The iron-nitrogen doped graphene has NADH oxidase-like activity, can directly catalyze the conversion of NADH into NAD + , can rapidly supplement NAD + depletion caused by radiation, can enhance PARP-dependent DNA damage repair, can reduce the generation of active oxygen (ROS), can reduce intestinal cell death and can protect the integrity of intestinal structure, and can realize efficient protection of radioactive enteritis. Moreover, the problem of low-efficiency biosynthesis of NAD + supplementation in existing radioactive intestinal injury protection technologies is solved.

The invention provides a medicine for preventing or treating enteritis. Hamp is adopted; and E, dyeing, determination of IL-6 factors in serum of each group of animals and the like are used for researching the influence of the vocyclosporine on intestinal tissues, mucosal barriers and immune systems of DSS or TNBS-induced mouse colitis models. Experimental basis is provided for clinical application of the vocyclosporine in preparation of the colitis treatment medicine, and the vocyclosporine has good application prospects and huge potential value and social significance.

The invention discloses a traditional Chinese medicine composition, a decoction, granules and application thereof. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 5-15 parts of radix scutellariae, 3-7 parts of rhizoma coptidis, 5-15 parts of radix puerariae, 5-15 parts of radix paeoniae alba, 8-16 parts of radix angelicae sinensis, 5-15 parts of raw radix sanguisorbae, 10-20 parts of herba portulacae, 4-8 parts of radix aucklandiae and 3-7 parts of honey-fried licorice root. The traditional Chinese medicine composition not only can directly act on the cause of damp-heat, but also can comprehensively cover enteritis symptoms such as abdominal pain, diarrhea, tenesmus, bloody purulent stool and the like, can relieve the disadvantage that the stomach is injured by bitter and cold medicines, is strong in clinical pertinence, and is suitable for enteritis caused by ulcerative colitis, bacteria, viruses, radioactivity and the like; the traditional Chinese medicine composition can also be matched with probiotics to treat western medicine chronic diarrhea and traditional Chinese medicine diarrhea. Therefore, the traditional Chinese medicine composition or the decoction and the granules thereof have the prospect of being developed into the medicine for treating enteritis or the prospect of being developed into the medicine for treating western medicine chronic diarrhea and traditional Chinese medicine diarrhea in cooperation with the probiotics.

The invention relates to a novel polypeptide and application thereof. The polypeptide provided by the invention is short in peptide chain and faster and better in absorption. Experimental results show that the polypeptide provided by the invention shows an obvious enteric cavity dilatation relieving effect in pharmacodynamic tests of a zebra fish inflammatory bowel disease model and a rat inflammatory bowel disease model. The polypeptide provided by the invention has a remarkable colitis relieving effect, and can be used for preparing a medicine for treating enteritis, especially a medicine for treating ulcerative colitis.

The invention discloses a probiotic biofilm gel microsphere as well as a preparation method and application thereof, and the probiotic biofilm gel microsphere is prepared by taking pectin, sodium alginate, escherichia coli Nissle1917 and iron-sulfur nano-enzyme as raw materials, preparing the raw materials through a microfluidic technology and then culturing the raw materials. The preparation method comprises the following steps: dissolving pectin and sodium alginate in deionized water, sequentially adding iron-sulfur nano-enzyme and Escherichia coli Nissle1917 into the deionized water, uniformly stirring, preparing through a microfluidic technology, and carrying out biological in-situ culture to make probiotics in the solution form a biological membrane. The cultured probiotic biofilm gel microspheres not only have the advantages of high stress resistance, good biocompatibility and the like, but also have good application prospects in the aspects of combined treatment and recovery of inflammatory enteritis and the like.

The application provides an EcNc engineering bacterium constitutively expressing MLH protein and application in treating intestinal inflammation, and belongs to the technical field of biological medicine. The application provides an EcNc engineering bacterium constitutively expressing MLH protein, taking Escherichia coli Nissle 1917 (EcN) as a chassis cell, and then introducing the reconstructed endogenous cryptic plasmid pMUT1 and / or pMUT2 after removing two hidden plasmids; the reconstruction is that a fusion protein MLH coding gene formed by using a flexible linker to connect SOD and CAT is inserted into pMUT1 and / or pMUT2. The application constructs an engineering bacterium constitutively expressing a fusion protein, and the engineering bacterium can express the fusion protein with double enzyme activities of SOD and CAT without antibiotic pressure and IPTG induction. The engineering bacterium constructed by the application can be used as an engineered microorganism for treating UC disease, for example, as a live bacterial drug.

The present application relates to a kind of high flux anaerobic intestinal chip system and the application in the function of evaluating probiotic bacteria to alleviate enteritis, high flux anaerobic intestinal chip system includes microfluidic chip, fluid perfusion device, oxygen monitoring chip and micro anaerobic box, fluid perfusion device can inject culture medium into microfluidic chip, oxygen monitoring chip is arranged in microfluidic chip upstream, microfluidic chip is arranged in micro anaerobic box, microfluidic chip is equipped with intestinal cell, high flux anaerobic intestinal chip can simulate intestinal environment, by different kinds of probiotic bacteria are added to intestinal chip, can be obtained by detecting culture product, or detecting intestinal cell after culture, to evaluate probiotic bacteria function;Further can combine high flux anaerobic intestinal chip with machine learning, utilize machine learning technology to analyze and process the multidimensional data characteristics (gene, protein, cell level) of enteritis model based on intestinal chip, to carry out global, overall comprehensive evaluation;Realize high flux, intelligent screening of better efficacy probiotic bacteria strain finally.

The invention provides a benzylimidazole glutamine cyclase inhibitor as well as a preparation method and application thereof, and belongs to the field of medical chemistry. The compound as shown in the formula I is prepared, the compound has good inhibitory activity on glutamine cyclase, and the half inhibitory concentration of most compounds reaches the nanomole level; the compound has a wide application prospect in preparation of drugs for treating Alzheimer's disease, depression, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, tumor, synovial membrane disease, gout, acute / chronic enteritis, rheumatoid arthritis or inflammatory diseases, and lays a material basis for research and development of related drugs.

The invention relates to the technical field of prevention and control of aquatic diseases, in particular to a preparation method of a pelteobagrus fulvidraco intestinal inflammation composite regulation preparation containing omega-3 fatty acid-lipoxin-phospholipid. The composite regulation and control preparation is prepared from the following functional components: 20 to 30 parts of eicosapentaenoic acid, 0.1 to 0.5 part of lipoxin B4, 8 to 12 parts of phosphatidylserine, 1 to 2 parts of dehydroabietic acid, 10 to 18 parts of sophorobiose and 0.01 to 0.03 part of ethoxyquin. The product integrates the functions of resisting bacteria, promoting inflammation regression and promoting tissue repair through a multi-target synergistic mechanism to construct a complete inflammation regulation and control pathway; meanwhile, by virtue of a nano-liposome dosage form technology, the active ingredients are effectively protected; the product is completely compounded from natural components to realize an antibacterial effect. According to the technical scheme, the technical problems of low antibacterial efficiency, single action mechanism, insufficient mucous membrane repair capability and the like of the existing prevention and control technology for the intestinal inflammation of the pelteobagrus fulvidraco can be solved, and the pelteobagrus fulvidraco has an ideal application prospect.

The invention relates to a big data screening method of a traditional Chinese medicine compound for treating enteritis and application thereof, and belongs to the field of traditional Chinese medicine screening based on a data mining technology, animal experiment efficacy investigation and network pharmacology prediction. Comprising the following steps: performing data arrangement specification on a traditional Chinese medicine compound for treating enteritis based on a data mining technology; analyzing and summarizing the standardized data to obtain a new traditional Chinese medicine compound (AEND); constructing an acute enteritis mouse model, and performing pharmacodynamic evaluation on the traditional Chinese medicine compound; predicting the action mechanism of the screened traditional Chinese medicine compound based on a network pharmacology method; a molecular docking technology is applied to virtually verify the action target of the traditional Chinese medicine compound on acute enteritis; the pathway protein of a mammalian cell receptor tyrosine kinase mediated phosphatidylinositol related (PI3K / AKT) signal pathway is detected. According to the invention, a new formula AEND is screened out based on data mining, and a pharmacological experiment verifies that the AEND has a protective effect on mice with acute enteritis. The developed traditional Chinese medicine compound has the effects of resisting inflammation and regulating the homeostasis of intestinal flora.

The invention discloses an application of an AC13 compound or a pharmaceutical salt thereof in preparation of a medicine for treating enteritis. The structure of the AC13 compound is shown in the specification. The AC13 compound disclosed by the invention has a remarkable treatment effect on enteritis as a small molecule compound, and has the characteristics of low toxicity and remarkable curative effect. Therefore, the AC13 compound can be used as a lead compound of the major disease enteritis, has important development prospects and clinical application values, and also provides a scientific basis for further exploring the enteritis pathogenesis mechanism.

The invention provides an extract with high saikoside B2 content, a preparation method and application of the extract, and a combined medicine containing the extract, and belongs to the technical field of natural medicine preparation. The method comprises the following steps: efficiently extracting saikoside A and saikoside D in a radix bupleuri raw material by using an alkaline ethanol solution, further realizing efficient resolution of saikoside A and saikoside D by using macroporous adsorption resin, and quantitatively converting saikoside D into saikoside B2 by using a chemical method, thereby obtaining the high-content effective part of saikoside B2. The high-content effective part of saikoside B2 only contains a small amount of saikoside A except the main component saikoside B2, so that the toxicity is greatly reduced while the biological activity of the saikoside B2 is ensured. The high-content effective part of saikosaponin B2 can be used for preparing medicines for treating and preventing gout, rheumatoid arthritis, acute enteritis, skin light injury, skin inflammation and other diseases, can be independently used, and can also be combined with other medicines for use.

The present application relates to a kind of compound preparation for preventing and treating poultry enteritis diarrhea, it is mainly made of the following weight parts proportion raw materials: catnip 10-12 parts, 10-12 parts of banlangen, 8-10 parts of heartleaf hedyotis, 10-12 parts of pepper, 10-15 parts of green wormwood, 8-10 parts of Chinese clematis, 10-12 parts of atractylodes, 3-5 parts of xylo-oligosaccharide, 1-3 parts of garlicin, 1-3 parts of capsaicin, 5-7 parts of vitamin C, 0.1-0.3 parts of vitamin A, 4-5 parts of bacillus licheniformis, 4-5 parts of butyric acid clostridium, 10-12 parts of brown sugar.The compound preparation can effectively improve the immune function of organism, prevent and treat diarrhea caused by poultry enteritis, improve intestinal health;While preparation enters organism, is easily absorbed, and clinical administration is convenient, suitable for group administration, save manpower and material resources.